Related Experiment Videos

Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats

Y Ban1, R Konishi, K Kawana

  • 1Development Research Laboratories, Banyu Pharmaceutical Co., Ltd. Saitama, Japan.

Archives of Toxicology
|January 1, 1994
PubMed

Insights

The antiarrhythmic drug L-691,121 significantly reduced embryonic survival and caused malformations in rats. This drug, which blocks potassium currents, showed a critical period for embryotoxicity between gestational days 10-13.

Area of Science:

  • Pharmacology
  • Developmental Toxicology
  • Cardiology

Background:

  • L-691,121 is a class III antiarrhythmic agent.
  • It functions by blocking potassium currents, prolonging cardiac potential, and preventing cardiac arrhythmia.

Purpose of the Study:

  • To investigate the developmental toxicity of L-691,121 in a rat model.
  • To determine the critical period for embryolethality and explore the mechanism of toxicity.

Main Methods:

  • Developmental toxicity study in pregnant rats.
  • Dose-response assessment for embryonic/fetal survival.
  • In vitro incubation of rat embryos with L-691,121 to assess cardiac function.

Main Results:

  • A dose-dependent decrease in embryonic/fetal survival was observed.
  • Lethal effects occurred at an oral dose of 0.8 mg/kg/day, with a critical period on gestational days 10-13.
  • Surviving embryos exhibited morphological abnormalities, and in vitro studies showed drug-induced decreases in embryonic heart rates.

Conclusions:

  • L-691,121 exhibits significant embryolethality and teratogenicity in rats.
  • The drug's mechanism may involve direct effects on embryonic cardiac function.
  • Caution is advised regarding L-691,121 use during pregnancy due to developmental risks.

Related Concept Videos